Osteotech, Inc. (OSTE) news stock charts
Osteotech, Inc. (OSTE) Investment Summary:
Information contained throughout this Annual Report contains “forward-looking statements” which can be identified by the use of forward-looking terminology such as “believes,” “expects,” “may”, “will”, “should”, or “anticipates” or the negative thereof or variations thereon or comparable terminology, or by discussions of strategy. No assurance can be given that the future results covered by the forward-looking statements will be achieved. Some of the matters set forth in the “Risk Factors” section of this Annual Report and elsewhere in this Annual Report constitute cautionary statements identifying factors with respect to such forward-looking statements, including certain risks and uncertainties that could cause results to vary materially from the future results indicated in such forward-looking statements. Other factors could also cause actual results to vary materially from the future results indicated in such forward-looking statements. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f03%2f12%2f0000950123-08-002860.html#FIS_BUSINESS"www.osteotech.com
Founded in 1986
OSTEOTECH INC (OSTE:NASDAQ)
LAST $4.13 USD
CHANGE TODAY -0.02 -0.48%
VOLUME 48.4K
As of 8:10 PM 03/19/10 All times are local (Market data is delayed by at least 15 minutes).
Snapshot of OSTEOTECH INC (OSTE)
|
OPEN
$4.18
|
PREVIOUS CLOSE
$4.15
|
|
|
DAY HIGH
$4.28
|
DAY LOW
$4.00
|
|
|
52 WEEK HIGH
07/30/09 - $5.04
|
52 WEEK LOW
11/27/09 - $2.55
|
|
|
MARKET CAP
74.7M
|
AVERAGE VOLUME 10 D
69.2K
|
|
|
EPS TTM
$-0.22
|
SHARES OUTSTANDING
18.1M
|
|
|
OSTE Does Not Pay Dividends
|
P/E TTM
--
|
|
| K = Thousands M = Millions B = Billions | ||
related news
Stocks Move Higher
12/26/2008 4:22 PM ET
Post-Christmas trading was slow on Friday. GMAC will become a bank holding company, while Amazon.com said its holiday season was busy
Key developments for OSTEOTECH INC (OSTE)
Osteotech, Inc. expected to Report Q1 2010 Results on April 26, 2010. This event was calculated by Capital IQ (Created on March 4, 2010).
03/4/2010
Osteotech, Inc. expected to Report Q1 2010 Results on April 26, 2010. This event was calculated by Capital IQ (Created on March 4, 2010).
Osteotech, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2009; Provides Earnings Guidance for the Year 2010
03/4/2010
Osteotech, Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2009. Revenue for the three months ended December 31, 2009 was $26.3 million, including $1.0 million from new products, compared with $24.6 million for the three months ended December 31, 2008. The increase in revenue for the fourth quarter of 2009 compared with the same period of 2008 was primarily driven by the $3.3 million in revenue realized from an agreement to license certain of the Company's tissue processing technology. This increase in revenue was partially offset by the anticipated reduction in revenue from the client services business and a decline in domestic unit sales volume. Excluding client services, private label dematerialized bone matrix and the license agreement revenue, fourth quarter 2009 revenue declined 3% compared with fourth quarter 2008 revenue. Net income for the fourth quarter ended December 31, 2009 was $890,000, or $0.05 per diluted share, compared with net loss of $409,000, or $0.02 per share, for the fourth quarter of 2008. For the quarter, the company reported operating income of $1.3 million and income before income taxes of $0.9 million compared to operating loss of $0.2 million and loss before income taxes of $0.5 million for the same period a year ago. Revenue for the full year ended December 31, 2009 was $96.7 million compared with $103.8 million reported for 2008. New product revenue was $1.3 million for 2009. The decline in revenue for the year was primarily driven by: the anticipated reduction in revenue from the company's services businesses, which declined $6.4 million; a decline in international revenue reflecting the challenging general economic conditions and the impact from the temporary suspension of tissue products from the company's Bulgarian subsidiary instituted in December 2008 and removed in late July 2009; and lower domestic unit sales volume. This decline was partially offset by the revenue received in conjunction with the company's aforementioned license agreement. Net loss for the full year ended December 31, 2009 was $4.0 million, or $0.22 per share, compared with net income of $2.2 million, or $0.12 per diluted share, for 2008. The net loss in 2009 is primarily due to the company's anticipated reductions in service revenue and the resulting lower gross margins. Net loss for 2009 was partially offset by the $2.3 million in profit that the Company's agreement to license certain tissue processing technology contributed to net income. For the year, the company reported operating loss of $2.9 million and loss before income taxes of $4.2 million compared to operating income of $2.5 million and income before income taxes of $2.4 million for the same period a year ago. The company provided financial guidance for 2010. Total revenue is expected to range between $97 million and $101 million, with between $10 million and $12 million in revenue stemming from new products; and Net income is expected to range between breakeven and a loss of $0.05 per share.
Osteotech, Inc. to Report Q4, 2009 Results on 03/04/2010
02/25/2010
Osteotech, Inc. announced that they will report Q4, 2009 results on 03/04/2010
Osteotech, Inc. financial resources
OSTE Competitors
| Company | Last | Change |
| Alphatec Holdings Inc | $6.80 USD | +0.16 |
| CryoLife Inc | $6.63 USD | -0.17 |
| Orthovita Inc | $4.18 USD | -0.13 |
| RTI Biologics Inc | $4.30 USD | +0.02 |
| Synovis Life Technologies Inc | $15.56 USD | -0.21 |
| Market data is delayed at least 15 minutes. | ||
Industry Analysis
| Valuation | OSTE | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 0.8x |
|
| Price/Book | 0.9x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 0.5x |
|
|
OSTE |
||
|
OSTE transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
More Recent Financial News About Osteotech, Inc.
Osteotech Reports Fourth Quarter and Full Year 2009 Financial Results
2010-03-10 04:06:50
Quote:  A replay of the call will be available two hours after completion of the live call through midnight, Thursday, March 18, 2010 by dialing 1-888-286-8010 and indicating access code 47904889.About OsteotechOsteotech, Inc., headquartered in Eatontown, New Jerseywww.osteotech.com.Certain statements made throughout this press release that are not historical facts are forward-looking statements (as defined in the Private Securities Litigation Reform Act of 1995) regarding the Company’s futur...Read article
Osteotech's MagniFuse(TM) Distributed to 68 U.S. Hospitals as Product Revenue Surpasses $1 Million
2010-03-10 04:06:49
Quote: Â About OsteotechOsteotech, Inc., headquartered in Eatontown, New Jerseywww.osteotech.com.Certain statements made throughout this press release that are not historical facts are forward-looking statements (as defined in the Private Securities Litigation Reform Act of 1995) regarding the Company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and u...Read article
Osteotech's MagniFuse(TM) Distributed to 68 U.S. Hospitals as Product Revenue Surpasses $1 Million
2010-03-09 02:11:21
Quote: Â About OsteotechOsteotech, Inc., headquartered in Eatontown, New Jerseywww.osteotech.com.Certain statements made throughout this press release that are not historical facts are forward-looking statements (as defined in the Private Securities Litigation Reform Act of 1995) regarding the Company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and u...Read article
Osteotech Reports Fourth Quarter and Full Year 2009 Financial Results
2010-03-05 04:40:23
Quote:  A replay of the call will be available two hours after completion of the live call through midnight, Thursday, March 18, 2010 by dialing 1-888-286-8010 and indicating access code 47904889.About OsteotechOsteotech, Inc., headquartered in Eatontown, New Jerseywww.osteotech.com.Certain statements made throughout this press release that are not historical facts are forward-looking statements (as defined in the Private Securities Litigation Reform Act of 1995) regarding the Company’s futur...Read article
OSTEOTECH INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
2010-03-05 04:40:22
Quote: Item 2.02 Results of Operations and Financial Condition.
On March 4, 2010, Osteotech, Inc. issued a press release announcing its
financial results for the quarter and year ended December 31, 2009. A copy of
the press release is attached hereto as Exhibit 99.1, which is incorporated
herein by reference.
The information furnished herewith pursuant to Item 2.02 of this Current
Report and in Exhibit 99.1 hereto shall not be deemed to be "filed" for the
purposes of Section 18 of the Securi...Read article
Osteotech, Inc 4Q 2009 & Full-Year Financial Results Call scheduled for 9:00 am ET today
2010-03-04 04:49:01
Quote: Call DetailsOsteotech, Inc 4Q 2009 & Full-Year Financial Results Conference CallScheduled
to start Thu, Mar 4, 2010, 9:00 am EasternAfter
the event has finished, the audio will be availablefrom
this page until Sat, Mar 5, 2011About OsteotechOSTE)Osteotech, Inc. develops biologic products for orthopedic, spinal, trauma, neurosurgical, and oral/maxillofacial surgeons for use in various surgical procedures. It operates in five segments: Demineralized Bone Matrix (DBM), Hybrid/Synthetic, Traditi...Read article
Osteotech Announces Preliminary Fourth Quarter 2009 Revenue
2010-01-26 05:05:48
Quote: 14 /PRNewswire-FirstCall/ -- Osteotech, Inc. (Nasdaq: OSTE), a leader in the emerging field of biologic products for regenerative healing, today reported preliminary unaudited revenue for the fourth quarter of 2009 of $26.3 million compared with $24.6 million for the same period in 2008. Â During the fourth quarter, the Company generated $1.0 million in revenue from sales of its new innovative products all currently in limited launch phases. Â Revenue in the fourth quarter of 2009 also inclu...Read article
Osteotech, Inc. Adopts Stockholder Rights Plan
2010-01-26 05:05:47
Quote: 22 /PRNewswire-FirstCall/ -- Osteotech, Inc. (Nasdaq: OSTE), a leader in the emerging field of biologic products for regenerative healing, announced today that its Board of Directors adopted a Stockholder Rights Plan. Â The rights plan is designed to discourage coercive or unfair takeover tactics and to provide fair and equal treatment for all stockholders of the Company in the event that an unsolicited offer is made to acquire the Company. Â To implement the rights plan, the Board authorize...Read article
OSTEOTECH INC Files SEC form 8-K, Entry into a Material Definitive Agreement
2010-01-25 01:06:43
Quote: A copy of the press release is furnished herewith
as Exhibit 99.1.
Item 9.01Financial Statements and Exhibits.
(d) Exhibits.
3.1Certificate of Designations of Series E Junior Participating Preferred
Stock, as filed with the Secretary of State of the State of Delaware on
January 22, 2010.
4.1Rights Agreement, dated as of January 22, 2010, between Osteotech, Inc. and
Registrar and Transfer Company, as Rights Agent, including the form of
Certificate of Designations of Series E Junior Participatin...Read article
Osteotech, Inc. Adopts Stockholder Rights Plan
2010-01-25 01:06:43
Quote: 22 /PRNewswire-FirstCall/ -- Osteotech, Inc. (Nasdaq: OSTE), a leader in the emerging field of biologic products for regenerative healing, announced today that its Board of Directors adopted a Stockholder Rights Plan. Â The rights plan is designed to discourage coercive or unfair takeover tactics and to provide fair and equal treatment for all stockholders of the Company in the event that an unsolicited offer is made to acquire the Company. Â To implement the rights plan, the Board authorize...Read article
Osteotech Announces Preliminary Fourth Quarter 2009 Revenue
2010-01-15 02:04:18
Quote: 14 /PRNewswire-FirstCall/ -- Osteotech, Inc. (Nasdaq: OSTE), a leader in the emerging field of biologic products for regenerative healing, today reported preliminary unaudited revenue for the fourth quarter of 2009 of $26.3 million compared with $24.6 million for the same period in 2008. Â During the fourth quarter, the Company generated $1.0 million in revenue from sales of its new innovative products all currently in limited launch phases. Â Revenue in the fourth quarter of 2009 also inclu...Read article
OSTEOTECH INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
2010-01-15 02:04:16
Quote: Item 2.02 Results of Operations and Financial Condition.
On January 14, 2010, Osteotech, Inc. issued a press release announcing certain
unaudited financial information for the quarter and year ended December 31,
2009. A copy of the press release is attached hereto as Exhibit 99.1, which is
incorporated herein by reference.
The information furnished herewith pursuant to Item 2.02 of this Current Report
and in Exhibit 99.1 hereto shall not be deemed to be "filed" for purposes of
Sectio...Read article
Osteotech Reports Third Quarter 2009 Financial Results
2010-01-12 02:57:02
Quote: All information in this press release is as of November 5, 2009 and the Company does not intend to update this information.OSTEOTECH, INC. and SubsidiariesCONSOLIDATED STATEMENTS OF OPERATIONS(dollars in thousands, except per share data)(unaudited)Three MonthsNine MonthsEndedEndedSeptember 30,September 30,2009200820092008Revenue$22,961$24,063$70,363$79,247Cost of Revenue12,50211,18236,40637,622Gross profit10,45912,88133,95741,625Marketing, selling andgeneral andadministrativeexpenses10,64810,476...Read article
Osteotech Submits 510(k) Application to FDA for Clearance of its Duratech(TM) BioRegeneration Matrix
2010-01-12 02:56:59
Quote: 17 /PRNewswire-FirstCall/ -- Osteotech, Inc. (Nasdaq: OSTE), a leader in the emerging field of biologic products for regenerative healing, announced today that it has submitted a 510(k) application to the United States Food and Drug Administration (FDA) to obtain marketing clearance for the use of its Duratechâ„¢ BioRegeneration Matrix to repair or replace the dura mater (the outermost membrane surrounding the brain) in various cranial surgical procedures. Â This filing is based, in part, ...Read article
OSTEOTECH INC Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance She
2010-01-06 02:47:50
Quote: Item 2.03.Creation of a Direct Financial Obligation or an Obligation under an
Off-Balance Sheet Arrangement for a Registrant.
On December 29, 2009, Osteotech, Inc. (the "Company") entered into a Revolving
Credit and Security Agreement (the "Credit Agreement") with PNC Bank, National
Association as lender and agent ("PNC"). Pursuant to the terms of the Credit
Agreement and upon request, the Company may borrow from PNC up to $10,000,000
(the "Maximum Revolving...Read article
Osteotech Submits 510(k) Application to FDA for Clearance of its Duratech(TM) BioRegeneration Matrix
2009-12-23 04:01:23
Quote: 17 /PRNewswire-FirstCall/ -- Osteotech, Inc. (Nasdaq: OSTE), a leader in the emerging field of biologic products for regenerative healing, announced today that it has submitted a 510(k) application to the United States Food and Drug Administration (FDA) to obtain marketing clearance for the use of its Duratechâ„¢ BioRegeneration Matrix to repair or replace the dura mater (the outermost membrane surrounding the brain) in various cranial surgical procedures. Â This filing is based, in part, ...Read article
Osteotech Secures 10-Year Tissue Supply Agreement
2009-11-30 04:29:46
Quote: Owusu-Akyaw continued, "Our goal is to be a vanguard in the development of novel, first-in-class bio-materials that will support and heighten advances in surgical techniques and patient outcomes through the use of innovative procedure-specific biologic products.Through our patented technology platforms, we have successfully begun to introduce a wide variety of advanced biologics with unique regenerative qualities and healing properties.""At CTS, we strive to be on the forefront of new graft deve...Read article
OSTEOTECH INC Files SEC form 8-K, Entry into a Material Definitive Agreement
2009-11-30 04:29:45
Quote: Entry into a Material Definitive Agreement.
On November 4, 2009, Osteotech, Inc. (the "Company") issued a press release
announcing its entry into a multi-year Tissue Recovery Agreement (the "Tissue
Recovery Agreement") with Community Blood Center d/b/a Community Tissue
Services, an Ohio nonprofit corporation ("CTS"), which recovers human bone and
other soft tissue for transplantation. A copy of the press release is attached
hereto as Exhibit 99.1, which is incorpo...Read article
Osteotech Reports Third Quarter 2009 Financial Results
2009-11-30 04:29:44
Quote: All information in this press release is as of November 5, 2009 and the Company does not intend to update this information.OSTEOTECH, INC. and SubsidiariesCONSOLIDATED STATEMENTS OF OPERATIONS(dollars in thousands, except per share data)(unaudited)Three MonthsNine MonthsEndedEndedSeptember 30,September 30,2009200820092008Revenue$22,961$24,063$70,363$79,247Cost of Revenue12,50211,18236,40637,622Gross profit10,45912,88133,95741,625Marketing, selling andgeneral andadministrativeexpenses10,64810,476...Read article
OSTEOTECH INC Files SEC form 8-K, Results of Operations and Financial Condition
2009-11-30 04:29:43
Quote: Item 2.02 Results of Operations and Financial Condition.
On November 5, 2009, Osteotech, Inc. issued a press release announcing its
financial results for the quarter ended September 30, 2009. A copy of the press
release is attached hereto as Exhibit 99.1, which is incorporated herein by
reference.
The information furnished herewith pursuant to Item 2.02 of this Current Report
and in Exhibit 99.1 hereto shall not be deemed to be "filed" for the purposes of
Section 18 of the Securiti...Read article
Would you like to leave a comment about Osteotech, Inc. OSTE
Find out what social network information about Osteotech, Inc. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Osteotech, Inc.'s Stock there is more great penny stock and market information at Realpennies